文献速递肝病消化道肿瘤与早癌

细胞外囊泡作为肝病生物标志物:临床医生视角

Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view.
PubMed 文献 · J Hepatol · 2020-07-15

本文综述了临床环境下测量细胞外囊泡浓度的方法(从血浆制备到测量技术)及其作为生物标志物的挑战,并全面回顾了细胞外囊泡作为诊断、严重程度和预后生物标志物在非酒精性和酒精性脂肪性肝炎、乙型和丙型病毒性肝炎、肝硬化、原发性肝癌、原发性硬化性胆管炎和急性肝衰竭中的研究。细胞外囊泡可能有助于评估非酒精性脂肪性肝病的活动度和纤维化、预测乙型肝炎病毒再激活风险、预测肝硬化并发症和死亡率、检测早期肝细胞癌、检测原发性硬化性胆管炎中的恶性转化以及预测急性肝衰竭的结局。多数研究基于仍需临床验证的先导研究数据,但部分细胞外囊泡亚群已在可靠的前瞻性研究中得到评估。

要点

  • 细胞外囊泡可反映来源细胞的生理和病理状态。
  • 细胞外囊泡可能用于评估非酒精性脂肪性肝病活动度和纤维化。
  • 部分细胞外囊泡亚群已在可靠前瞻性研究中评估,多数研究仍需临床验证。

核心结论

  • 细胞外囊泡可能作为多种肝病的诊断、严重程度和预后生物标志物,但多数研究基于仍需临床验证的先导研究数据,部分亚群已在可靠前瞻性研究中评估。

研究设计与样本

  • 综述,概述临床环境下测量细胞外囊泡浓度的方法(从血浆制备到测量技术)并回顾相关研究。

主要发现

  • 细胞外囊泡可能有助于评估非酒精性脂肪性肝病的活动度和纤维化。
  • 细胞外囊泡可能有助于预测乙型肝炎病毒再激活风险。
  • 细胞外囊泡可能有助于预测肝硬化并发症和死亡率。
  • 细胞外囊泡可能有助于检测早期肝细胞癌和原发性硬化性胆管炎中的恶性转化。
  • 细胞外囊泡可能有助于预测急性肝衰竭的结局。

局限性

  • 多数研究基于先导研究数据,仍需临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Extracellular vesicles are membrane-bound vesicles containing proteins, lipids, RNAs and microRNAs. They can originate from both healthy and stressed cells, and provide a snapshot of the cell of origin in physiological and pathological circumstances. Various processes that may give rise to the release of extracellular vesicles occur in liver diseases, including hepatocyte apoptosis, hepatic stellate cell activation, liver innate immune system activation, systemic inflammation, and organelle dysfunction (mitochondrial dysfunction and endoplasmic reticulum stress). Numerous studies have therefore investigated the potential role of extracellular vesicles as biomarkers in liver diseases. This review provides an overview of the methods that can be used to measure extracellular vesicle concentrations in clinical settings, ranging from plasma preparation to extracellular vesicle measurement techniques, as well as looking at the challenges of using extracellular vesicles as biomarkers. We also provide a comprehensive review of studies that test extracellular vesicles as diagnostic, severity and prognostic biomarkers in various liver diseases, including non-alcoholic and alcoholic steatohepatitis, viral hepatitis B and C infections, cirrhosis, primary liver cancers, primary sclerosing cholangitis and acute liver failure. In particular, extracellular vesicles could be useful tools to evaluate activity and fibrosis in non-alcoholic fatty liver disease, predict risk of hepatitis B virus reactivation, predict complications and mortality in cirrhosis, detect early hepatocellular carcinoma, detect malignant transformation in primary sclerosing cholangitis and predict outcomes in acute liver failure. While most studies draw on data derived from pilot studies, which still require clinical validation, some extracellular vesicle subpopulations have already been evaluated in solid prospective studies.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Thietart S, Rautou PE. Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view. J Hepatol. 2020. PMID: 32682050. doi:10.1016/j.jhep.2020.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。